Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CST 2032/nadolol

Drug Profile

CST 2032/nadolol

Alternative Names: CST-2032/CST-107; CST-2032/Naldol - Curasen Theraepeutics; CST2032/nadolol

Latest Information Update: 12 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CuraSen Therapeutics
  • Class Antidementias; Antihypertensives; Antimigraines; Class II antiarrhythmics; Ischaemic heart disorder therapies; Neuroprotectants; Propanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Beta-adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dementia; Mild cognitive impairment

Most Recent Events

  • 07 Mar 2024 Efficacy and adverse event data from phase IIa trial in Mild cognitive impairment and Dementia released by
  • 07 Mar 2024 CuraSen Therapeutics plans additional phase II trial for Mild Cognitive Impairment or Dementia from either Alzheimer’s or Parkinson’s disease
  • 31 Mar 2023 Efficacy and safety results were released by CuraSen Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top